Neurology Central

AAN 2017: Two clinical studies report promising data for new spinal muscular atrophy treatment


Two studies presented at the AAN Annual Meeting 2017 in Boston (MA, USA) have demonstrated positive results for nusinersen (Spinraza® Biogen (MA, USA) in the treatment of spinal muscular atrophy (SMA).

Restricted Content / Members Only

You cannot view this content because It is available to members only. Please or Register to view this area.